{"id":58629,"date":"2026-03-03T12:53:30","date_gmt":"2026-03-03T04:53:30","guid":{"rendered":"https:\/\/flcube.com\/?p=58629"},"modified":"2026-03-03T12:53:30","modified_gmt":"2026-03-03T04:53:30","slug":"cspc-pharmas-syhx2011g1-wins-fda-ind-approval-instant-release-albumin-bound-paclitaxel-for-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58629","title":{"rendered":"CSPC Pharma’s SYHX2011G1 Wins FDA IND Approval \u2013 Instant\u2011Release Albumin\u2011Bound Paclitaxel for Metastatic Breast Cancer"},"content":{"rendered":"\n

CSPC Pharmaceutical Group Ltd (HKG:\u202f1093<\/a>)<\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved an Investigational New Drug (IND)<\/strong> application for SYHX2011G1<\/strong>, an injectable albumin\u2011bound paclitaxel nanosuspension (instant\u2011release formulation)<\/strong>. The drug will be assessed in metastatic breast cancer<\/strong> that has failed combination chemotherapy<\/strong> or relapsed within six months of adjuvant chemotherapy<\/strong>, targeting a high\u2011unmet\u2011need patient population with limited effective options.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>CSPC Pharmaceutical Group Ltd (HKG:\u202f1093)<\/td><\/tr>
Product<\/strong><\/td>SYHX2011G1<\/td><\/tr>
Drug Class<\/strong><\/td>Injectable albumin\u2011bound paclitaxel nanosuspension (instant\u2011release)<\/td><\/tr>
Regulatory Body<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Regulatory Action<\/strong><\/td>IND approval for clinical study<\/td><\/tr>
Indication<\/strong><\/td>Metastatic breast cancer (post\u2011combination chemo failure or early relapse)<\/td><\/tr>
Innovation Status<\/strong><\/td>Expected to be world’s first instant\u2011release albumin\u2011bound paclitaxel<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Taxane Context & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Taxane Class<\/strong><\/td>Most commonly used and effective cytotoxic chemo for advanced breast cancer<\/td><\/tr>
Clinical Benefit<\/strong><\/td>Significantly greater survival vs. other chemotherapy agents (monotherapy or combination)<\/td><\/tr>
Current Limitations<\/strong><\/td>Existing albumin\u2011bound paclitaxel (Abraxane) requires infusion; instant\u2011release formulation may enable faster administration<\/td><\/tr>
Target Population<\/strong><\/td>Heavily pretreated metastatic breast cancer with limited therapeutic options<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Differentiation<\/h2>\n\n\n\n
Feature<\/th>SYHX2011G1<\/th>Abraxane (Reference)<\/th><\/tr><\/thead>
Formulation<\/strong><\/td>Instant\u2011release nanosuspension<\/strong><\/td>Standard albumin\u2011bound nanoparticle<\/td><\/tr>
Release Kinetics<\/strong><\/td>Rapid drug availability<\/td>Sustained release profile<\/td><\/tr>
Administration<\/strong><\/td>Potentially faster infusion\/shorter infusion time<\/td>Standard infusion duration<\/td><\/tr>
Innovation<\/strong><\/td>Next\u2011generation proprietary technology<\/strong><\/td>First\u2011generation albumin\u2011bound paclitaxel<\/td><\/tr>
Global Status<\/strong><\/td>Expected first instant\u2011release formulation<\/strong><\/td>Established standard of care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n